Report
David Nikoski

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.
Underlying
Acadia Healthcare Company Inc.

Acadia Healthcare Company is a holding company. Through its subsidiaries, the company provides behavioral healthcare services, with operations in the U.S. and the U.K. The company's U.S. facilities and services are divided into four categories: acute inpatient psychiatric facilities; specialty treatment facilities; residential treatment centers; and outpatient community-based services. In the U.K., the company provides inpatient services through facilities, including mental health hospitals, clinics, care homes, schools, colleges and children's homes. The company's U.K. facilities and services can be divided into the following categories: healthcare facilities, education and children's services, and adult care facilities.

Provider
Vermilion Research
Vermilion Research

Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.

Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.

Analysts
David Nikoski

Other Reports on these Companies
Other Reports from Vermilion Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch